BioLine Rx (XTAE:BLRX) Inventories, Finished Goods : ₪0.00 Mil (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Inventories, Finished Goods?

BioLine Rx's annual finished goods stayed the same from Dec. 2021 (₪0.00 Mil) to Dec. 2022 (₪0.00 Mil) but then increased from Dec. 2022 (₪0.00 Mil) to Dec. 2023 (₪2.07 Mil).

BioLine Rx Inventories, Finished Goods Historical Data

The historical data trend for BioLine Rx's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Inventories, Finished Goods Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

2.07

BioLine Rx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Inventories, Finished Goods	Get a 7-Day Free Trial															-	2.07	-	-	-

BioLine Rx Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

BioLine Rx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.